Development of <sup>11</sup>C‐labeled CRANAD‐102 for positron emission tomography imaging of soluble Aβ‐species-Reference-Cited by-同舟云学术

Development of ¹¹C‐labeled CRANAD‐102 for positron emission tomography imaging of soluble Aβ‐species

Published:2023-08-31 Issue:12 Volume:66 Page:393-399
ISSN:0362-4803
Container-title:Journal of Labelled Compounds and Radiopharmaceuticals
language:en
Short-container-title:Labelled Comp Radiopharmac

Author:

Staudt Markus¹^ORCID,Shalgunov Vladimir¹²,Nedergaard Maiken³⁴,Herth Matthias M.¹⁵^ORCID

Affiliation:

1. Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

2. Cluster for Molecular Imaging, Department of Biomedical Sciences University of Copenhagen Copenhagen Denmark

3. Center for Translational Neuromedicine, Department of Neurosurgery University of Rochester Medical Center Rochester New York USA

4. Center for Translational Neuromedicine, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

5. Department of Clinical Physiology Nuclear Medicine & PET, Rigshospitalet Copenhagen Denmark

Abstract

CRANAD‐102, a selective near‐infrared fluorescent tracer targeting soluble amyloid‐β (Aβ) species, has recently attracted attention due to its potential to be used as a diagnostic tool for early stages of Alzheimer's disease (AD). Development of a positron emission tomography (PET) tracer based on CRANAD‐102 could as such allow to noninvasively study soluble and protofibrillar species of Aβ in humans. These soluble and protofibrillar species are thought to be responsible to cause AD. Within this work, we successfully 11C‐labeled CRANAD‐102 via a Suzuki–Miyaura reaction in a RCС of 48 ± 9%, with a RCP of >96% and a molar activity (Am) of 25 ± 7 GBq/μmol. Future studies have to be conducted to evaluate if [11C]CRANAD‐102 can be used to detect soluble protofibrils in vivo and if [11C]CRANAD‐102 can be used to detect AD earlier as possible with current diagnostics.

Funder

Danmarks Frie Forskningsfond

Publisher

Wiley

Subject

Organic Chemistry,Spectroscopy,Drug Discovery,Radiology, Nuclear Medicine and imaging,Biochemistry,Analytical Chemistry

Reference23 articles.

1. The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer’s Disease—Review of Literature and Interesting Images

2. A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers

3. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

4. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes